Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC.ASMB · Entity 5216 | Director | May 25, 2022 | May 27, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ASSEMBLY BIOSCIENCES, INC.
Report date May 25, 2022 · Filed May 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.69 · Expires 2032-05-25 | Direct | 20,000 |
Reported balance
After 2022-05-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-25 · Grant · Acquired 20,000 · Balance 20,000 F1: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 25, 2023 and (2) the date of the Issuer's 2023 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 25, 2023 and (2) the date of the Issuer's 2023 annual meeting of stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 25, 2022 Filed May 27, 2022 20:31 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001209191-22-032562 · doc4.xml · derivative · entry 1 DiMarchi Richard D · CIK 0001311733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-05-25 F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 25, 2023 and (2) the date of the Issuer's 2023 annual meeting of stockholders. Read SEC document |
| May 20, 2021 Filed May 24, 2021 20:57 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001209191-21-035379 · doc4.xml · derivative · entry 1 DiMarchi Richard D · CIK 0001311733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-05-20 F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 20, 2022 and (2) the date of the Issuer's 2022 annual meeting of stockholders. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 20:40 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $20.47 | $0.00 |
DisclosureSEC source: 0001209191-20-036630 · doc4.xml · derivative · entry 1 DiMarchi Richard D · CIK 0001311733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-06-11 F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 11, 2021 and (2) the date of the Issuer's 2021 annual meeting of stockholders. Read SEC document |
| May 17, 2019 Filed May 17, 2019 23:33 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $15.22 | $0.00 |
DisclosureSEC source: 0001144204-19-027157 · tv521920_4.xml · derivative · entry 1 DiMarchi Richard D · CIK 0001311733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-05-17 F1 · derivative.exercise_date: The shares of common stock underlying the option will vest upon the earlier of (i) May 17, 2020 and (ii) the date of the Issuer's 2020 annual meeting of stockholders. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 21:52 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $42.09 | $0.00 |
DisclosureSEC source: 0001144204-18-032474 · tv495565_4.xml · derivative · entry 1 DiMarchi Richard D · CIK 0001311733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2028-05-30 F1 · derivative.exercise_date: The shares of common stock underlying the option will vest upon the earlier of (i) May 30, 2019 and (ii) the date of the Issuer's 2019 annual meeting of stockholders. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:32 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $25.96 | $0.00 |
DisclosureSEC source: 0001144204-17-031033 · v468319_4.xml · derivative · entry 1 DiMarchi Richard D · CIK 0001311733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2027-06-01 F1 · derivative.exercise_date: The shares of Common Stock underlying the option will vest upon the earlier of (i) June 1, 2018 and (ii) the date of the Issuer's 2018 annual meeting of stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.